Calamos Advisors’s Revance Therapeutics, Inc. RVNC Stock Holding History

Calamos Advisors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-24,923	Closed	-$631K	–	1003
2023 Q2	$631K	Buy	24,923 +16,811	+207%	+$524K	﹤0.01%	735
2023 Q1	$261K	Sell	8,112 -5,684	-41%	-$177K	﹤0.01%	878
2022 Q4	$255K	Sell	13,796 -63,874	-82%	-$1.46M	﹤0.01%	940
2022 Q3	$2.1M	Buy	+77,670	New	+$1.58M	0.01%	868
2020 Q4	–	Sell	-62,599	Closed	-$1.57M	–	769
2020 Q3	$1.57M	Buy	62,599 +29,473	+89%	+$773K	0.01%	615
2020 Q2	$809K	Buy	+33,126	New	+$654K	0.01%	652

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Calamos Advisors's RVNC Position: Q3 2023 in Review

Calamos Advisors sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 24,923 shares — an estimated $631K sold.

Calamos Advisors first reported a position in RVNC in Q2 2020 and held it in 6 quarters. The position peaked at $2.1M in Q3 2022. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

Calamos Advisors reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
Calamos Advisors sold 24,923 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $631K.
Calamos Advisors first reported a position in Revance Therapeutics, Inc. in Q2 2020 and held it in 6 quarters.
Calamos Advisors's Revance Therapeutics, Inc. position peaked at $2.1M in Q3 2022.
186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on Calamos Advisors's 13F filing for Q3 2023, filed 26 Oct 2023.